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Purpose/Objective: The purpose of this study is to evaluate 
our first experience with 3D image-guided breast 
brachytherapy (BT) and to compare dose distribution 
parameters between Paris dosimetry treatment plans and 
image-based treatment plans. 
Materials and Methods: First, 49 consecutive breast cancer 
patients treated with high dose rate (HDR) interstitial 
brachytherapy were selected for the study. All patients 
received 10Gy boost dose after whole breast irradiation. 
Every patient underwent computed tomography and the 
planning target volume (PTV) and organs at risk (OAR) were 
outlined. Two treatment plans were created for every 
patient. First, based on a Paris dosimetry system (PDS), and 
the second one, imaged-based plan with graphical 
optimization (OPT). The reference isodose in PDS implants 
was 85%, whereas in OPT plans the isodose was chosen to 
obtain proper target coverage. Dose and volume parameters 
(D90, D100, V90, V100), dose at OARs, total reference air 
kerma (TRAK) and quality assurance parameters: dose 
nonuniformity ratio (DNR), dose homogeneity index (DHI), 
external volume index (EI) and conformal index (COIN) were 
used for a comparison of both plans. 
Results: One-, two-, three-plane implants were used. The 
mean number of catheters was 7, but the mean for first 20 
patients was 5 and almost 9 catheters for the next 29 
patients. The volume of PTV ranged from 13,6 cm3 to 163,4 
cm3 (mean: 58,2 cm3). The mean value of isodose selected 
for prescribing the dose for OPT plans was 73%. The mean 
D90 was 88,2% and 105,8%, the D100 was 59,8% and 75,7%, 
the V90 was 88,6% and 98,1%, the V100 was 79,9% and 98,9% 
and the TRAK was 0,00375 Gym-1 and 0,00439 Gym-1 for the 
PDS and OPT plans respectively. The mean DNR was 0,29 and 
0,42, the DHI was 0,71 and 0,58, the EI was 0,15 and 0,23 
and the COIN was 0,68 and 0,76 respectively. All differences 
are statistically significant. 
Conclusions: The target coverage in image-guided plans 
(OPT) was significantly higher than in plans based on Paris 
dosimetry system (PDS), but the dose homogeneity was 
worse. Also value of TRAK increased because of change of 
prescribing isodose. Our first experience proved, that more 
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Purpose/Objective: The aim of our study is to describe the 
technique used in our center to plan and administer 
treatment with high dose rate (HDR) brachytherapy using CT 
simulation and 3D dosimetry to evaluate the dose in organs at 
risk by dose-volume histograms. Also describe the acute 
toxicity observed since the beginning of this modality of 
treatment in our center (6 years). 
Materials and Methods: The unit used to administer the 
treatment is a Varian Gammamed Plus, and the applicator 
used in all cases is a vaginal cylinder with diameters of the 
segments between 20 mm and 35 mm. Planification and 
dosimetry was performed using Brachyvision software. 
The planning and treatment protocol is as follows: 
- Physical examination and determination of the applicator to 
be used. 
- Bladder catheterisation. 
- Vaginal cylinder placement. 
- CT simulation. 
- Determination of PTV (vaginal cylinder + 5 mm margin) and 
the volumes of organs at risk. 
- Dosimetry. 
- Administration of treatment. 
We used 2 different schedules: 
From September 2008 to September 2012: 
- Treatment after external radiotherapy (46 Gy): 15 Gy in 3 
sessions separated at least 48 hours. 
- Treatment with exclusive brachytherapy: 30 Gy in 6 sessions 
separated at least 48 hours. 
From October 2012 to November 2014: 
- Treatment after external radiotherapy (46 Gy): 14 Gy in 2 
sessions separated at least 48 hours. 
- Treatment with exclusive brachytherapy: 28 Gy in 4 sessions 
separated at least 48 hours. 
Toxicity was recorded according to RTOG criteria before 
every session. 
Results: From September 2008 to November 2014 we treated 
261 patients with this technique. All patients completed 
treatment with the planned dose. In no case was necessary to 
chamge the treatment schedule because of toxicity. 
The average duration of the planning was 30 minutes.  
All the treatments were complementary after surgery. The 
postoperative histology was adenocarcinoma in 210 patients 
(80.5%), papillary serous carcinoma in 19 patients (7.3%), 
sarcoma in 14 patients (5.3%) , carcinosarcoma in 10 patients 
(3.9%), and clear cell carcinoma in 8 patients (3%). 
In 50.5% of the cases the treatment was performed as a boost 
after external radiotherapy and in the other 49.5% was 
exclusive brachytherapy. 
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Conclusions: The treatment planification of HDR 
brachytherapy with CT images and 3D dosimetry allows to 
know the dose received in the volume of the organs at risk 
and also a good optimisation of the treatment. 
The treatment was very well tolerated and there was no 
grade 3-4 toxicity in our patients.  
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Purpose/Objective: Toxicity evaluation of exclusive adjuvant 
vaginal cuff High Dose Rate Brachytherapy (HDR-BT) in 
patients with endometrial cancer. 
Materials and Methods: From 2009 to date, 53 patients were 
treated in our institution with HDR-BT, with a median age of 
65 years. 52 patients underwent hysterectomy for 
endometrioid cancer and 1 for transitional cell carcinoma. 
FIGO and grading staging were 14-IA, 35-IB, 4-IIA, 8-G1, 31-
G2, 14-G3. No patients received external-beam radiation 
therapy or chemotherapy. Before Computed Tomography (CT) 
simulation, women underwent a gynecological examination in 
order to determine the size of the vaginal cylinder that will 
fit the patient. CT simulation was performed with 2.5 mm CT 
slice thickness with empty rectum and the treatment cylinder 
in the vaginal cavity. Before CT scan patients drank 500 cc of 
water after voiding bladder ; this preparation was repeated 
before each fraction in order to reproduce bladder's filling 
conditions used for the planning. Upper 3-3.5 cm of the 
vaginal vault were treated. Patients received five fractions 
each of 600 cGy for a total dose of 3000 cGy prescribed at 
0.5 cm from the applicator surface. During the radiation 
therapy course, patients received supportive therapy with 
hyaluronic acid vaginal suppositories. A low-fat diet with the 
addition of lactobacilli was suggested. Use of vaginal dilators 
was not prescribed. Gastrointestinal (GI) and Genitourinary 
(GU) toxicity were evaluated by RTOG score. Late toxicity 
effects were also analysed in 26 patients with a median 
follow-up of 37 months by using the RTOG late-effect score. 
According to our protocol, gynaecological exams were 
scheduled every 3 months for two years and then every 6 
months up to five years. 
Results: Eighteen patients experienced acute GU toxicity: 10 
Grade 1 (G-1), 6 G-2, and 2 G-3. Regarding early GI toxicity, 
9 cases of G-1 toxicity and 2 of G-2 occurred.Four patients 
experienced GU late toxicity: 3 G-2 and 1 G-3. No one 
complained of GI late toxicity. Ten patients presented 
vaginal stenosis during the gynaecological examinations. This 
side effect made the patients' follow-up difficult because of 
greater difficulty in viewing the vaginal vault; also four 
women complained of dyspareunia 
Conclusions: In our experience, vaginal-vault HDR-BT 
treatment is well tolerated, with a very low GI toxicity score. 
Vaginal stenosis appears to be the principal disorder observed 
in long-term follow-up. In order to improve this safe 
technique, we think that could be reasonable to prescribe 
the use of the vaginal dilator not in all patients, but only in 
those women in which the stenosis occur. 
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Purpose/Objective: The aim of this study was to assess 
through radiobiological evaluation the ability of the hybrid 
inverse planning optimization (HIPO) system to produce dose 
distributions comparable or superior to the clinically 
accepted ones devised using graphical optimization (GRO) for 
cervical cancer patients treated with pulsed-dose-rate 
brachytherapy. 
Materials and Methods: Six cervical cancer patients treated 
with external radiotherapy and pulsed-dose-rate 
brachytherapy were included in this study. The patients 
received 50 Gy (25 x 2 Gy) as external radiotherapy and 24 
Gy (3 x 8 Gy) as pulsed-dose-rate brachytherapy planned 
using GRO performed in Oncentra® Brachy treatment 
planning (Nucletron, an Elekta Company). An alternative 
brachytherapy plan was made in HIPO using volumetric 
